0bdec778-829d-4cba-8d0f-dcaa0d8803b1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.400
- BILE_ACID_METABOLISM+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- PROTEIN_SECRETION+0.300
- TGF_BETA_SIGNALING+0.300
- COMPLEMENT+0.200
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.500
- MYC_TARGETS_V1-0.400
- HYPOXIA-0.300
- SPERMATOGENESIS-0.300
- ESTROGEN_RESPONSE_LATE-0.200
- GLYCOLYSIS-0.200
- HEDGEHOG_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1JB-01A-11R-A13Q-07 | — | A | 0.867 |
| 2 | TCGA-A2-A0YI-01A-31R-A10J-07 | — | A | 0.857 |
| 3 | TCGA-78-8655-01A-11R-2403-07 | — | cohortA1 | 0.824 |
| 4 | DRR168557 | — | — | 0.822 |
| 5 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.820 |
| 6 | TCGA-97-7552-01A-11R-2039-07 | — | cohortA1 | 0.817 |
| 7 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.816 |
| 8 | TCGA-78-7539-01A-11R-2066-07 | — | cohortA1 | 0.811 |
| 9 | TCGA-97-A4LX-01A-11R-A24X-07 | — | cohortA1 | 0.806 |
| 10 | TCGA-BH-A1EU-01A-11R-A137-07 | — | A | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |